Free Trial

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives $6.64 Consensus Target Price from Analysts

Maravai LifeSciences logo with Medical background

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) have received an average rating of "Hold" from the twelve brokerages that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $6.64.

A number of research firms have recently issued reports on MRVI. Morgan Stanley cut their price objective on Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating for the company in a research report on Tuesday, March 25th. UBS Group cut their price target on Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating for the company in a report on Friday, March 21st. Robert W. Baird decreased their price objective on shares of Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. Craig Hallum dropped their price objective on shares of Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Finally, Stifel Nicolaus set a $5.00 target price on shares of Maravai LifeSciences in a report on Friday, March 21st.

Read Our Latest Stock Report on Maravai LifeSciences

Maravai LifeSciences Stock Up 6.2%

Shares of MRVI stock traded up $0.16 during trading on Friday, reaching $2.76. The company's stock had a trading volume of 2,461,569 shares, compared to its average volume of 2,290,926. Maravai LifeSciences has a one year low of $1.67 and a one year high of $10.03. The business has a fifty day moving average price of $2.24 and a 200-day moving average price of $3.14. The company has a market cap of $702.86 million, a price-to-earnings ratio of -2.42 and a beta of 0.28. The company has a quick ratio of 5.17, a current ratio of 5.96 and a debt-to-equity ratio of 0.60.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The company had revenue of $46.85 million for the quarter, compared to the consensus estimate of $44.01 million. Maravai LifeSciences had a negative return on equity of 12.91% and a negative net margin of 67.14%. The company's revenue was down 26.9% compared to the same quarter last year. Analysts anticipate that Maravai LifeSciences will post -0.24 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Performa Ltd US LLC lifted its position in shares of Maravai LifeSciences by 614.3% during the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company's stock valued at $27,000 after acquiring an additional 4,300 shares during the period. Farther Finance Advisors LLC lifted its position in Maravai LifeSciences by 3,541.4% during the fourth quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company's stock worth $56,000 after purchasing an additional 9,916 shares during the period. Cibc World Markets Corp acquired a new stake in Maravai LifeSciences during the fourth quarter worth about $56,000. Atria Investments Inc acquired a new stake in Maravai LifeSciences during the fourth quarter worth about $58,000. Finally, McAdam LLC bought a new position in Maravai LifeSciences in the 1st quarter valued at about $31,000. 50.25% of the stock is owned by institutional investors.

About Maravai LifeSciences

(Get Free Report

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

Featured Stories

Analyst Recommendations for Maravai LifeSciences (NASDAQ:MRVI)

Should You Invest $1,000 in Maravai LifeSciences Right Now?

Before you consider Maravai LifeSciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list.

While Maravai LifeSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines